Shares of Xeris Pharmaceuticals Inc (NASDAQ: XERS) rallied 5.16% in pre-market trading on Thursday, following the company's outstanding fourth quarter and full-year 2024 financial results, along with upbeat revenue guidance for 2025.

For the fourth quarter, Xeris reported record total revenue of $60.1 million, up 35.4% year-over-year, driven by strong sales growth of its key products Gvoke and Recorlev. Net revenue for Gvoke, the company's ready-to-use liquid glucagon for severe hypoglycemia, rose 24.8% to $23.3 million, while Recorlev, a treatment for endogenous Cushing's syndrome, more than doubled its revenue to $22.6 million, reflecting a 130.6% increase.

The robust quarterly performance translated into a record full-year 2024 revenue of $203.1 million, up 23.9% compared to the prior year. Gvoke and Recorlev continued their momentum throughout the year, with revenue growth of 23.5% and 117.5%, respectively.

Furthermore, Xeris achieved positive cash flow and Adjusted EBITDA of $8.3 million in the fourth quarter, highlighting the company's improving financial position and operational efficiency.

Looking ahead, Xeris provided an optimistic revenue guidance for 2025, projecting total revenue in the range of $255 million to $275 million, representing growth of over 30% at the mid-point of the range. This strong outlook reflects the company's confidence in continued market share gains and expanding demand for its innovative product portfolio.